Axcella Health Inc. - Common Stock (NQ:AXLA)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 22, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axcella Health Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 21, 2022

Gainers Biophytis (NASDAQ:BPTS) shares rose 12.3% to $5.28 during Friday's regular session. The market value of their outstanding shares is at $68.0 million. Intra-...

Via Benzinga

Axcella Therapeutics Details Clinical and Operational Milestones for 2022

January 06, 2022

From Axcella Therapeutics

Via Business Wire

Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference

January 04, 2022

From Axcella Therapeutics

Via Business Wire

Axcella Kickstarts Long COVID Phase 2 Clinical Trial ↗

December 16, 2021

Axcella Therapeutics Inc (NASDAQ: AXLA) has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long...

Via Benzinga

Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

December 16, 2021

From Axcella Therapeutics

Via Business Wire

Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer

December 06, 2021

From Axcella Therapeutics

Via Business Wire

Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

November 18, 2021

From Axcella Therapeutics

Via Business Wire

Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials

November 10, 2021

From Axcella Therapeutics

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 08, 2021

Gainers Kiromic BioPharma (NASDAQ:KRBP) ...

Via Benzinga

Axcella Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2021

November 02, 2021

From Axcella Therapeutics

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 27, 2021

Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock...

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Axcella To Test NASH Candidate In Long COVID Patients ↗

October 26, 2021

Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last...

Via Benzinga

64 Biggest Movers From Yesterday ↗

October 28, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc...

Via Benzinga

Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID

October 26, 2021

From Axcella Therapeutics

Via Business Wire

60 Biggest Movers From Yesterday ↗

October 27, 2021

Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the...

Via Benzinga

Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021

October 19, 2021

From Axcella Therapeutics

Via Business Wire

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗

October 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

Axcella Announces Upcoming Investor Conference Presentation

October 05, 2021

From Axcella

Via Business Wire

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

Axcella's Leading Drug Candidate for Overt Hepatic Encephalopathy Offers Hope in a Market Requiring Innovation ↗

September 28, 2021

Image by Ousa Chea on Unsplash The clinical-stage biotech company Axcella (NASDAQ: AXLA) uses endogenous metabolic modulators (EMMs) to treat complex diseases, including liver...

Via Benzinga

Axcella Health Inc. (NASDAQ: AXLA) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference

September 24, 2021

Via Investor Brand Network

Topics Derivatives

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 ↗

September 22, 2021

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

September 22, 2021

Piper Sandler boosted the price target for Adobe Inc. (NASDAQ: ADBE) from $600 to $670. Adobe shares fell 3.5% to $623.50 in pre-market trading. Keybanc reduced the price target...

Via Benzinga

Axcella's First-of-Its-Kind NASH Treatment Shows Promising Early Results in Human Trials ↗

September 09, 2021

Image Provided By Pixabay The American Journal of Gastroenterology recently published findings from a clinical study of AXA1125, a groundbreaking potential treatment for...

Via Benzinga

Axcella Announces Upcoming Investor Conference Presentation

September 07, 2021

From Axcella

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 01, 2021

Gainers INmune Bio (NASDAQ:INMB) shares ...

Via Benzinga

Breakthrough Multi-Targeted Drug Candidates Puts Axcella at Forefront of Liver Disease Treatment Market ↗

August 30, 2021

Image Provided By Unsplash Liver diseases like cirrhosis and nonalcoholic steatohepatitis (NASH) are deadly and afflict millions of Americans with debilitating mental and physical...

Via Benzinga

Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH

August 16, 2021

From Axcella

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.